<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               4 CONTRAINDICATIONS<BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           <BR>                              •History of intracranial hemorrhage (4.1)<BR>                           <BR>                              •Active pathological bleeding (4.2)<BR>                           <BR>                              •Severe hepatic impairment (4.3)<BR>                           <BR>                              •<BR>                              Hypersensitivity to ticagrelor or any component of the product (4.4)<BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     4.1 History of Intracranial Hemorrhage<BR>                     <BR>                        BRILINTA is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     4.2 Active Bleeding<BR>                     <BR>                        BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     4.3 Severe Hepatic Impairment<BR>                     <BR>                        BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins [see Clinical Pharmacology (12.3)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        4.4 Hypersensitivity<BR>                     <BR>                     <BR>                        <BR>                           BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product [see Adverse Reactions (6.2)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>